Jay Bott
Hematology & Oncology · Orem, UTNPI 1164524864
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,663 and has fallen 98.8% since, to $20 in 2022. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 123 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$235
- Novartis$165
- Pfizer$145
- Incyte Corporation$144
- AstraZeneca$144
- Puma Biotechnology, Inc.$137
- plus $1K from 23 others
What the payments were for
- Food & beverage$1,80791%
- Education$1709%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 27 | $235 |
| Novartis | 11 | $165 |
| Pfizer | 9 | $145 |
| Incyte Corporation | 5 | $144 |
| AstraZeneca | 10 | $144 |
| Puma Biotechnology, Inc. | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $121 |
| Johnson & Johnson(2 entities) | 5 | $84 |
| Lilly USA, LLC | 5 | $82 |
| Amgen | 4 | $78 |
| Merck | 5 | $70 |
| Tesaro, Inc. | 3 | $63 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $62 |
| Eisai Inc. | 3 | $57 |
| EMD Serono, Inc. | 3 | $48 |
| Bristol Myers Squibb | 1 | $41 |
| Foundation Medicine, Inc. | 3 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Bayer | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Spectrum Pharmaceuticals Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| AbbVie | 1 | $16 |
How this compares
$1,978 in reported general payments places this provider in the 45th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Orem
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Terence RhodesCedar City$147K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.